Clinical Trials Logo

Healthy Adults clinical trials

View clinical trials related to Healthy Adults.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT04933656 Not yet recruiting - Healthy Adults Clinical Trials

Use of Stable Carbon And Nitrogen Isotopes to Improve Dietary Assessment for Cardiovascular Disease

I-CAN
Start date: August 2021
Phase: N/A
Study type: Interventional

In this research study, the investigators will use a novel approach to measure what people eat. The goal is to find out whether stable isotopes that can be measured in blood, hair, and fingernails are better at measuring what people eat than the surveys that are currently used. To meet the goal, the investigators will do three things. First, the investigators will feed study participants known amounts of foods and nutrients. Second, after study participants have eaten the food, the investigators will measure stable isotopes in samples of study participants' blood, hair, and fingernails. Third, the investigators will determine how well these samples reflect what was eaten. The investigators will also give surveys to study participants to determine how well the surveys reflect what was eaten. This will allow the investigators to do a relative comparison of the measurements from isotopes and surveys.

NCT ID: NCT04198636 Not yet recruiting - Healthy Adults Clinical Trials

A Study to Evaluate LY01011 and Xgeva® in Healthy Adults

Start date: December 16, 2019
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, single-dose, parallel-group study to compare the pharmacokinetics, pharmacodynamics, safety and immunogenicity of LY01011 and Xgeva® in healthy adults

NCT ID: NCT02113306 Not yet recruiting - Healthy Adults Clinical Trials

Does Transcutaneous Vagal Nerve Stimulation Improves Fear Extinction in Humans

t-VNSext
Start date: July 2014
Phase: N/A
Study type: Interventional

A recent study with rats showed that electrical stimulation of the vagus nerve (VNS) facilitates extinction of fear (Pena, Engineer, & McIntyre, Biological Psychiatry, 2013). The hypothesized mechanism is that VNS both enhances memory consolidation (by increasing noradrenergic neurotransmission) and reduces anxiety (thus: preventing fear responses to the CS which may re-consolidate the fear memory). The effect was only apparent when VNS occurred during exposure of the fear conditioned stimulus (CS), and not when stimulation was given immediately following exposure. These results may have implications for the treatment of anxiety disorders in humans. However, until recently, the only means to investigate the effects of VNS on human fear learning would have required the invasive implantation of vagus nerve stimulators. This has fortunately changed, as a non-invasive transcutaneous VNS device has been approved for use in the E.U. for the treatment of psychological disorders. This study proposes to use a t-VNS to investigate its effects on fear learning and extinction in (healthy) humans. Previous research has only investigated the effects it has on human mood and memory. The results obtained suggest that it reduces negative affect and enhances memory, findings which are consistent with those reported for rats. It is thus reasonable to expect that t-VNS will facilitate the extinction of fear in humans. The present study aims to answer the following research questions: Does t-VNS during extinction training: 1. accelerates extinction curves 2. reduces spontaneous recovery of previously extinguished fear 3. reduce re-acquisition of fear 4. reduce generalization of fear to other stimuli that resemble the CS+? 5. facilitates the generalization of inhibitory learning to stimuli that resemble the CS-?